Soligenix, Inc Stock News

Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage b

PRINCETON, N.J. , May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t

PRINCETON, N.J. , May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t

Includes thermostabilized Ebola vaccines MarVax™ and SuVax™ Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON, N.J. , April 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:

PRINCETON, N.J. , April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing product

Soligenix (NASDAQ:SNGX) shares surged more than 44% after the biopharmaceutical company won Orphan Drug Designation from US regulators for the active ingredient in its MarVax vaccine for Marburg Marbu

Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday! Stocks are up today as retail data came in better than expected

Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Monday after getting an orphan drug designation for the active ingredient in MarVax. This comes from the Food and Drug Administration's (FDA) Off

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval  PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp

Provides SuVax™   Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Com

Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study PRINCETON, N.J. , April 3, 2024 /PRNewswire/ -- Sol

PRINCETON, N.J. , March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to

Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J. , Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biophar

ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show

PRINCETON, N.J. , Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to